about
Transfusion strategies for acute upper gastrointestinal bleeding.Metabolomics as a diagnostic tool for idiopathic non-cirrhotic portal hypertension.Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues.Reduced hepatic stellate cell expression of Kruppel-like factor 6 tumor suppressor isoforms amplifies fibrosis during acute and chronic rodent liver injury.Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.Pathogenesis of liver fibrosis.Medical therapies for hepatocellular carcinoma: a critical view of the evidence.Management of small hepatocellular carcinoma in cirrhosis: focus on portal hypertension.Variceal and other portal hypertension related bleeding.Drugs plus ligation to prevent rebleeding in cirrhosis: an updated systematic review.Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design.Endoscopic hemostasis in acute esophageal variceal bleeding.Clinical Evaluation and Prognosis.Nontumoral portal vein thrombosis in patients awaiting liver transplantation.Timing Affects Measurement of Portal Pressure Gradient After Placement of Transjugular Intrahepatic Portosystemic Shunts in Patients With Portal Hypertension.Autophagy and mesenchymal cell fibrogenesis.Cross-talk between autophagy and KLF2 determines endothelial cell phenotype and microvascular function in acute liver injury.Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis.A randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis.The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique.Impact of anticoagulation on upper-gastrointestinal bleeding in cirrhosis. A retrospective multicenter study.[Idiopathic non-cirrhotic portal hypertension].Relative adrenal insufficiency in severe acute variceal and non-variceal bleeding: influence on outcomes.Idiopathic portal hypertension: natural history and long-term outcome.A prospective observational study on tolerance and satisfaction to hepatic haemodynamic procedures.Role of albumin treatment in patients with spontaneous bacterial peritonitis.Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding.Real-time shear-wave elastography: applicability, reliability and accuracy for clinically significant portal hypertension.The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells.The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis.Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis.[Early transjugular intrahepatic portosystemic shunt: When, how and in whom?].Unexpected disappearance of portal cavernoma on long-term anticoagulation.Obeticholic acid: a new light in the shadows treating portal hypertension?DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma.Transjugular Liver BiopsyDevelopment of Ascites in Compensated Cirrhosis With Severe Portal Hypertension Treated With β-BlockersPreemptive‐TIPS Improves Outcome in High‐Risk Variceal Bleeding: An Observational StudyThe Endothelium as a Driver of Liver Fibrosis and RegenerationCongenital antithrombin deficiency in patients with splanchnic vein thrombosis
P50
Q34320493-B75EC924-FE89-4A33-9B4F-AF12249AD4EDQ35783812-E7BA83C2-1D39-429F-83A4-33243C08E715Q36227227-435D529C-AB3F-4529-9FF7-D38A8E9B238CQ36467939-F374F3B1-DEC4-44F6-9472-3021F416DC3BQ36625697-69F39C62-CA65-4FEA-95FC-DE8ABC93D6FCQ37809079-23DE1BF0-4079-4529-B005-63D69F0C3797Q38059437-B4ADE624-B684-4E19-9490-62F3B091B498Q38088585-6892CE40-011E-4DD7-ADF0-B3C000E6C63FQ38155632-57A6A38B-87A3-4081-83A1-5750A7BB392BQ38174281-5A27FA00-ACBE-4608-9A9A-E298AC089966Q38192888-1B02A284-320D-4A23-B7B8-0C1A98159F43Q38273944-7BE04823-4102-4158-89DD-E6683F4F9905Q38544490-3DA95716-0399-407B-9045-A643209D672DQ38673769-3067AD26-8B9D-44F1-9013-8FA1DF6F1DA4Q38994735-4128605F-FBCD-4A2D-98B9-654C0EE8B199Q39319936-13AA9BCD-6272-4846-BD49-FBD2412DA503Q39469613-60045BA0-2E96-4C6A-AB65-D4035E2C0516Q39911150-982C5CA1-729B-4302-9A11-64BA3E056EC6Q40375007-C595E615-D78E-4846-B4E7-F66460AB4F6AQ40665105-4F0A3EF2-5480-48A1-841D-EA5F6FB74592Q41216205-8CA8B9B7-3F8E-4EBF-BBB9-CE9DEDB93484Q41438597-AC094272-7C46-4F8D-8169-31521D16DD31Q41508379-4AB8BF2D-8256-45E6-BC6D-C860DECE305FQ42260245-F49A9313-6D1C-450C-930B-6F3085C575E7Q44415194-5259605E-5CCB-4FF8-9786-DC6EF205E73CQ45911095-9D93BFCF-A674-41F3-A19B-898B4A0CB7AEQ46062290-B61C79B1-E72F-41E8-9463-1DF0677FA27DQ47771800-61050F9F-D4FA-4DBF-A4F3-7C0B750D1BD4Q48292789-3855DC6A-481F-4FA5-BF9B-F504990F8457Q50245155-70B499B1-485A-4FB5-A577-1C8893237FB3Q50266948-5E8C8E2D-391F-4965-A103-FA9A7DCCB807Q50277169-3E72ADD4-8B38-4B4F-86A2-813A940A484BQ50474530-8BD86954-40E9-46FD-9FE4-96CD0D7E67BBQ50480517-112C80C3-CE9B-4059-A6F9-3E9C19DA8A34Q51499838-4CC14617-2A82-421D-902C-443BC028AF6AQ60188752-B4599AEE-F416-4A33-B424-7A645D2D74B6Q60188843-C2835AB8-CD7E-4041-A8D3-782BF1DCD0D4Q64134540-D59EB91C-E178-45A3-929E-9448FBA58043Q91920875-B1478711-8A25-4115-8BA0-D86784AFB7D4Q92305654-3ED4734C-5AC3-4E0E-8208-B0730E84C8BC
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Virginia Hernandez-Gea
@ast
Virginia Hernandez-Gea
@en
Virginia Hernandez-Gea
@es
Virginia Hernandez-Gea
@nl
Virginia Hernandez-Gea
@sl
type
label
Virginia Hernandez-Gea
@ast
Virginia Hernandez-Gea
@en
Virginia Hernandez-Gea
@es
Virginia Hernandez-Gea
@nl
Virginia Hernandez-Gea
@sl
prefLabel
Virginia Hernandez-Gea
@ast
Virginia Hernandez-Gea
@en
Virginia Hernandez-Gea
@es
Virginia Hernandez-Gea
@nl
Virginia Hernandez-Gea
@sl
P1053
E-9485-2017
P106
P21
P31
P3829
P496
0000-0001-7937-984X